Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 8/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | MET | P08581 | 10/20 | 0.57 |
| ▸ | RIPK3 | Q9Y572 | 5/20 | 0.57 |
| ▸ | MERTK | Q12866 | 6/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722103 | 0.91 | MET (0.65) | AXLMETRIPK3MERTKCYP3A4 | |
| SCHEMBL16817176 | 0.89 | AXL (0.47) | AXLAURKAMETRIPK3MERTK | |
| SCHEMBL721795 | 0.87 | MET (0.55) | AXLAURKAMETRIPK3MERTK | |
| SCHEMBL721614 | 0.85 | AXL (0.60) | AXLMETMERTKLCKKIT | |
| SCHEMBL16817182 | 0.81 | AXL (0.47) | AXLAURKAMETMERTKLCK | |
| SCHEMBL16817179 | 0.80 | MET (0.51) | AXLMETRIPK3MERTKCYP3A4 | |
| SCHEMBL27366035 | 0.80 | MERTK (0.68) | AXLMETMERTKTYRO3 | |
| SCHEMBL2476315 | 0.79 | MET (0.70) | AXLAURKAMETRIPK3MERTK | |
| SCHEMBL724084 | 0.79 | MET (0.67) | AXLMETRIPK3MERTKCYP3A4 | |
| SCHEMBL23749519 | 0.78 | AURKA (0.62) | AXLAURKAMETRIPK3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | SYK, FCGRT, SSB | AXL 390/4885AURKA 1987/4885MET 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.